Fact Sheet  
  News Release  

DOR BioPharma Webcast
Monday, October 22, 2007
9:00am ET.

Call participants:
Domestic:
800.642.1687
Conference code: 21605507
International:
706.645.9291
Conference code: 21605507

Download conference call transcript

 
 

 

Crystal Research Associates, LLC

  Wall Street Advisors

 

Evan Myrianthopoulos
Chief Financial Officer
DOR BioPharma, Inc.
850 Bear Tavern Road, Suite 201
Ewing, New Jersey 08628
Tel: 609-538-8200
Fax: 609-538-8205
email

 

 

 

 
 
 
 


INVESTOR CENTER

DOR BioPharma, Inc.’s common stock is listed on the Over -The- Counter bulletin board securities market under the symbol “DORB”. Stockholders and interested parties are urged to contact our main office in Ewing, New Jersey at 609-538-8200 for further information.

FINANCIAL INFORMATION

DOR BioPharma Stock Quote (Over -The- Counter bulletin board securities market, symbol “DORB” ).
DOR BioPharma Filings with the SEC (link to EDGAR DATABASE)
DOR BioPharma Financial Releases
Code of Ethics for Senior Financial Officers

10QSB

Provides a comprehensive review of DOR BioPharma's financial position and operating results for the quarter and year-to-date. Offers a discussion of business activities, information about earnings and other measures of financial performance and unaudited financial statements and statistical data.
LINK to 10QSB on the EDGAR database

10KSB

Provides a description of DOR BioPharma's businesses, products and services, a comprehensive review of the company's financial position and operating results for the year, a discussion of business activities, information about earnings and other measures of financial performance and audited financial statements and footnotes. 
LINK to 10KSB on the EDGAR database

LITERATURE REQUEST:

If you would like to receive our Investor Relations Packet, including reprints of scientific publications relating to our products, please fill out the following form and click on “Submit”. Thank you for your interest.

 
 
Name   REQUIRED
Title    
Company    
Street Address   REQUIRED
Address (cont.)  
City   REQUIRED
State/Province   REQUIRED
ZIP/Postal Code   REQUIRED
Country  
Phone  
FAX  
Email   REQUIRED
URL  
 Investor Relations Packet
 Annual Report
 Financial Statements
 Please update my contact information.
 Please remove me from your mailing list.

 

 

 


The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The forward-looking statements contained in this release are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. Among the factors which could affect the Company's actual results and could cause results to differ from those contained in the forward-looking statements contained herein are: the timely commencement and success of the Company's clinical trials and other research endeavors, delays in receiving FDA or other regulatory approvals, the development of competing therapies and/or technologies, the terms of any future strategic alliances, the possible need for additional capital, and any additional factors described from time to time in the Company’s periodic reports on Form 10-KSB and 10-QSB, and any prospectus describing the Company’s securities.

Links to Third Party Sites:
Please understand that when you access another web site through this one, DOR BioPharma can accept no responsibility for your experience with the site. In addition, a link to a non-DOR BioPharma site does not mean that DOR BioPharma endorses or recommends that site or its contents.

Stock Information:
The information provided under "DOR BioPharma Stock Quote" in the Investor Center section of this site is provided through a hypertext link to a third party Web site. (See above for important information about links to third party Web sites.) Under no circumstances will DOR BioPharma be liable for any loss or direct, indirect, incidental, special or consequential damages caused by reliance on this information or for the risks of the stock market.

 

   
  Legal Notice
  Copyright © 2005 DOR BioPharma, Inc. 1999-2005 All rights reserved.